We are present to show and obtain feedback on a novel oral once daily Fixed Dose Combination Tablet which contains rifampicin and clarithromycin that could facilitate the treatment of Buruli Ulcer in endemic countries, especially in combination with a proper and timely diagnosis and advanced wound care.